NEW YORK – Roughly three years after its launch, the Applied Proteogenomics Organizational Learning and Outcomes (APOLLO) Network has moved beyond its initial focus on lung cancer to add analyses of multiple cancer types including a prospective, multisite study.

The network is also working to incorporate additional proteomic technologies including data-independent acquisition (DIA) mass spectrometry and imaging and top-down mass spec, said Thomas Conrads, director of women's health research at Inova Fairfax Hospital and a researcher on the APOLLO initiative.